Patents by Inventor Marie-Therese Melki

Marie-Therese Melki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for quantitating total HMGB1 protein in biological samples
    Patent number: 10012655
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: July 3, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
    Patent number: 9164103
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 20, 2015
    Assignee: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE
    Publication number: 20150056610
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: November 4, 2014
    Publication date: February 26, 2015
    Inventors: Marie-Lise GOUGEON, Hela SAIDI, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
    Patent number: 8906634
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 9, 2014
    Assignee: Institut Pasteur
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE
    Publication number: 20140120525
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 1, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise GOUGEON, Hela SAIDI, Marie-Therese MELKI, Beatrice POIRIER-BEAUDOIN, Valerie SEFFER
  • MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE
    Publication number: 20100158912
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: September 11, 2009
    Publication date: June 24, 2010
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer